Skip to main content
Erschienen in: Tumor Biology 4/2016

10.11.2015 | Original Article

Evaluation of prognostic factors in localized high-grade undifferentiated pleomorphic sarcoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology

verfasst von: Melike Ozcelik, Mesut Seker, Emrah Eraslan, Sinan Koca, Dogan Yazilitas, Ozlem Ercelep, Ersin Ozaslan, Serap Kaya, Ilhan Hacibekiroglu, Serkan Menekse, Asude Aksoy, Burcu Yapar Taskoylu, Umut Varol, Erkan Arpaci, Aydin Ciltas, Berna Oksuzoglu, Nurullah Zengin, Mahmut Gumus, Mehmet Aliustaoglu

Erschienen in: Tumor Biology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Most data on prognostic factors for patients with high-grade undifferentiated pleomorphic sarcoma (HGUPS) is obtained from analyses of soft tissue sarcomas. The purpose of this study was to evaluate the clinicopathologic features and their impact on outcomes specifically in patients diagnosed with HGUPS. In this multicenter trial, we retrospectively analyzed 112 patients who were diagnosed and treated at 12 different institutions in Turkey. We collected data concerning the patients, tumor characteristics, and treatment modalities. There were 69 males (61.6 %) and 43 females (38.4 %). Median age was 56 years (19–90). The most common anatomic site of tumor origin was the upper extremity. Pleomorphic variant was the predominant histological subtype. Median tumor size was 8.2 cm (0.6–30 cm). Tumors were mainly deeply seated (57.1 %). Fifty-seven patients (50.9 %) were stage II and the remainder were stage III at the time of diagnosis. Median follow-up was 30 months (2–160). The primary site of distant metastasis was the lung (73.5 %) and the second most common site was the liver (11.7 %). The 5-year overall survival, distant metastasis-free survival, and local recurrence-free survival rates were 56.3, 53.4, and 67.2 %, respectively. Multivariate analysis showed that Eastern Cooperative Oncology Group (ECOG) performance score of II (p = 0.033), deep tumor location (p = 0.000), and development of distant metastasis (p = 0.004) were negatively correlated with overall survival, and perioperative radiotherapy and negative microscopic margins were significant factors for local control rates (p = 0.000 for each). Deep tumor location (p = 0.003) was the only adverse factor related to distant metastasis-free survival. Deep tumor location, ECOG performance score of II, and development of distant metastasis carry a poor prognostic implication on overall survival. These will aid clinicians in predicting survival and treatment decision.
Literatur
2.
Zurück zum Zitat Dei Tos AP. Classification of pleomorphic sarcomas: where are we now? Histopathology. 2006;48:51–62.CrossRefPubMed Dei Tos AP. Classification of pleomorphic sarcomas: where are we now? Histopathology. 2006;48:51–62.CrossRefPubMed
3.
Zurück zum Zitat Massi D, Beltrami G, Capanna R, Franchi A. Histopathological re-classification of extremity pleomorphic soft tissue sarcoma has clinical relevance. Eur J Surg Oncol. 2004;30:1131–6.CrossRefPubMed Massi D, Beltrami G, Capanna R, Franchi A. Histopathological re-classification of extremity pleomorphic soft tissue sarcoma has clinical relevance. Eur J Surg Oncol. 2004;30:1131–6.CrossRefPubMed
4.
Zurück zum Zitat Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology. 2006;48:3–12.CrossRefPubMed Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology. 2006;48:3–12.CrossRefPubMed
5.
Zurück zum Zitat Kearney MM, Soule EH, Ivins JC. Malignant fibrous histiocytoma: a retrospective study of 167 cases. Cancer. 1980;45:167–78.CrossRefPubMed Kearney MM, Soule EH, Ivins JC. Malignant fibrous histiocytoma: a retrospective study of 167 cases. Cancer. 1980;45:167–78.CrossRefPubMed
6.
Zurück zum Zitat Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer. 1978;41:2250–66.CrossRefPubMed Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer. 1978;41:2250–66.CrossRefPubMed
7.
Zurück zum Zitat Leite C, Goodwin JW, Sinkovics JG, Baker LH, Benjamen R. Chemotherapy of malignant fibrous histiocytoma. A Southwest Oncology Group Report. Cancer. 1977;40:2010–14.CrossRefPubMed Leite C, Goodwin JW, Sinkovics JG, Baker LH, Benjamen R. Chemotherapy of malignant fibrous histiocytoma. A Southwest Oncology Group Report. Cancer. 1977;40:2010–14.CrossRefPubMed
8.
Zurück zum Zitat Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer. 2003;97(10):2530–43.CrossRefPubMed Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer. 2003;97(10):2530–43.CrossRefPubMed
9.
Zurück zum Zitat Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001;91(10):1914–26.CrossRefPubMed Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001;91(10):1914–26.CrossRefPubMed
10.
Zurück zum Zitat Toulmonde M, Le Cesne A, Mendiboure J, Blay JY, Piperno-Neumann S, Chevreau C, et al. Long-term recurrence of soft tissue sarcomas: prognostic factors and implications for prolonged follow-up. Cancer. 2014;120(19):3003–6.CrossRefPubMed Toulmonde M, Le Cesne A, Mendiboure J, Blay JY, Piperno-Neumann S, Chevreau C, et al. Long-term recurrence of soft tissue sarcomas: prognostic factors and implications for prolonged follow-up. Cancer. 2014;120(19):3003–6.CrossRefPubMed
11.
Zurück zum Zitat Maretty-Nielsen K, Aggerholm-Pedersen N, Safwat A, Jørgensen PH, Hansen BH, Baerentzen S, et al. Prognostic factors for local recurrence and mortality in adult soft tissue sarcoma of the extremities and trunk wall: a cohort study of 922 consecutive patients. Acta Orthop. 2014;85(3):323–32.CrossRefPubMedPubMedCentral Maretty-Nielsen K, Aggerholm-Pedersen N, Safwat A, Jørgensen PH, Hansen BH, Baerentzen S, et al. Prognostic factors for local recurrence and mortality in adult soft tissue sarcoma of the extremities and trunk wall: a cohort study of 922 consecutive patients. Acta Orthop. 2014;85(3):323–32.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Salcedo Hernández RA, Lino-Silva LS, de León DC, Herrera-Gómez Á, Martinez-Said H, Meneses-Garcia A. Importance of tumor size in soft tissue sarcomas: a proposal for a nomogram based on a score system to staging soft tissue sarcomas in the postoperative setting. Med Oncol. 2014;31(3):873.CrossRefPubMed Salcedo Hernández RA, Lino-Silva LS, de León DC, Herrera-Gómez Á, Martinez-Said H, Meneses-Garcia A. Importance of tumor size in soft tissue sarcomas: a proposal for a nomogram based on a score system to staging soft tissue sarcomas in the postoperative setting. Med Oncol. 2014;31(3):873.CrossRefPubMed
13.
Zurück zum Zitat Jones NB, Iwenofu H, Scharschmidt T, Kraybill W. Prognostic factors and staging for soft tissue sarcomas: an update. Surg Oncol Clin N Am. 2012;21(2):187–200.CrossRefPubMed Jones NB, Iwenofu H, Scharschmidt T, Kraybill W. Prognostic factors and staging for soft tissue sarcomas: an update. Surg Oncol Clin N Am. 2012;21(2):187–200.CrossRefPubMed
14.
Zurück zum Zitat Kempson RL, Kyriakos M. Fibroxanthosarcoma of the soft tissues—a type of malignant fibrous histiocytoma. Cancer. 1972;29:961–76.CrossRefPubMed Kempson RL, Kyriakos M. Fibroxanthosarcoma of the soft tissues—a type of malignant fibrous histiocytoma. Cancer. 1972;29:961–76.CrossRefPubMed
15.
Zurück zum Zitat Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer. 1977;39:1672–85.CrossRefPubMed Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer. 1977;39:1672–85.CrossRefPubMed
16.
Zurück zum Zitat Le Doussal V, Coindre JM, Leroux A, Hacene K, Terrier P, Bui NB, et al. Prognostic factors for patients with localized primary malignant fibrous histiocytoma: a multicenter study of 216 patients with multivariate analysis. Cancer. 1996;77(9):1823–30.CrossRefPubMed Le Doussal V, Coindre JM, Leroux A, Hacene K, Terrier P, Bui NB, et al. Prognostic factors for patients with localized primary malignant fibrous histiocytoma: a multicenter study of 216 patients with multivariate analysis. Cancer. 1996;77(9):1823–30.CrossRefPubMed
17.
Zurück zum Zitat Rööser B, Willén H, Gustafson P, Alvegård TA, Rydholm A. Malignant fibrous histiocytoma of soft tissue: a population-based epidemiologic and prognostic study of 137 patients. Cancer. 1991;67:499–505.CrossRefPubMed Rööser B, Willén H, Gustafson P, Alvegård TA, Rydholm A. Malignant fibrous histiocytoma of soft tissue: a population-based epidemiologic and prognostic study of 137 patients. Cancer. 1991;67:499–505.CrossRefPubMed
18.
Zurück zum Zitat Oda Y, Tamiya S, Oshiro Y, Hachitanda Y, Kinukawa N, Iwamoto Y, et al. Reassessment and clinicopathological prognostic factors of malignant fibrous histiocytoma of soft parts. Pathol Int. 2002;52(9):595–606.CrossRefPubMed Oda Y, Tamiya S, Oshiro Y, Hachitanda Y, Kinukawa N, Iwamoto Y, et al. Reassessment and clinicopathological prognostic factors of malignant fibrous histiocytoma of soft parts. Pathol Int. 2002;52(9):595–606.CrossRefPubMed
19.
Zurück zum Zitat Pezzi CM, Rawlings MS, Esgro JJ, Pollock RE. Prognostic factors in 227 patients with malignant fibrous histiocytoma. Cancer. 1992;69:2098–103.CrossRefPubMed Pezzi CM, Rawlings MS, Esgro JJ, Pollock RE. Prognostic factors in 227 patients with malignant fibrous histiocytoma. Cancer. 1992;69:2098–103.CrossRefPubMed
20.
Zurück zum Zitat Belal A, Kandil A, Allam A, Khafaga Y. Malignant fibrous histiocytoma: a retrospective study of 109 cases. Am J Clin Oncol. 2002;25:16–22.CrossRefPubMed Belal A, Kandil A, Allam A, Khafaga Y. Malignant fibrous histiocytoma: a retrospective study of 109 cases. Am J Clin Oncol. 2002;25:16–22.CrossRefPubMed
21.
Zurück zum Zitat Engellau J, Persson A, Bendahl PO, Akerman M, Domanski HA, Bjerkehagen B, et al. Expression profiling using tissue microarray in 211 malignant fibrous histiocytomas confirms the prognostic value of Ki-67. Virchows Arch. 2004;445(3):224–30.CrossRefPubMed Engellau J, Persson A, Bendahl PO, Akerman M, Domanski HA, Bjerkehagen B, et al. Expression profiling using tissue microarray in 211 malignant fibrous histiocytomas confirms the prognostic value of Ki-67. Virchows Arch. 2004;445(3):224–30.CrossRefPubMed
22.
Zurück zum Zitat Vasileios KA, Eward WC, Brigman BE. Surgical treatment and prognosis in patients with high-grade soft tissue malignant fibrous histiocytoma of the extremities. Arch Orthop Trauma Surg. 2012;132(7):955–61.CrossRefPubMed Vasileios KA, Eward WC, Brigman BE. Surgical treatment and prognosis in patients with high-grade soft tissue malignant fibrous histiocytoma of the extremities. Arch Orthop Trauma Surg. 2012;132(7):955–61.CrossRefPubMed
23.
Zurück zum Zitat Hsu HC, Huang EY, Wang CJ. Treatment results and prognostic factors in patients with malignant fibrous histiocytoma. Acta Oncol. 2004;43(6):530–5.CrossRefPubMed Hsu HC, Huang EY, Wang CJ. Treatment results and prognostic factors in patients with malignant fibrous histiocytoma. Acta Oncol. 2004;43(6):530–5.CrossRefPubMed
24.
Zurück zum Zitat Li GX, Guo W. Analysis of therapeutic strategies and prognostic factors of malignant fibrous histiocytoma of soft tissue. Zhonghua Wai Ke Za Zhi. 2011;49(11):974–7.PubMed Li GX, Guo W. Analysis of therapeutic strategies and prognostic factors of malignant fibrous histiocytoma of soft tissue. Zhonghua Wai Ke Za Zhi. 2011;49(11):974–7.PubMed
25.
Zurück zum Zitat Kim MS, Cho WH, Song WS, Lee SY, Jeon DG. Prognostic significance of ezrin expression in pleomorphic malignant fibrous histiocytoma. Anticancer Res. 2007;27:1171–8.PubMed Kim MS, Cho WH, Song WS, Lee SY, Jeon DG. Prognostic significance of ezrin expression in pleomorphic malignant fibrous histiocytoma. Anticancer Res. 2007;27:1171–8.PubMed
26.
Zurück zum Zitat Lehnhardt M, Daigeler A, Homann HH, Schwaiberger V, Goertz O, Kuhnen C, et al. MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities—an analysis of 140 patients. Langenbecks Arch Surg. 2009;394(2):313–20.CrossRefPubMed Lehnhardt M, Daigeler A, Homann HH, Schwaiberger V, Goertz O, Kuhnen C, et al. MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities—an analysis of 140 patients. Langenbecks Arch Surg. 2009;394(2):313–20.CrossRefPubMed
27.
Zurück zum Zitat Antman KH. Adjuvant therapy of sarcomas of soft tissue. Semin Oncol. 1997;24(5):556–60.PubMed Antman KH. Adjuvant therapy of sarcomas of soft tissue. Semin Oncol. 1997;24(5):556–60.PubMed
28.
Zurück zum Zitat Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19(5):1238–47.CrossRefPubMed Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19(5):1238–47.CrossRefPubMed
29.
Zurück zum Zitat Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.CrossRefPubMed Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.CrossRefPubMed
Metadaten
Titel
Evaluation of prognostic factors in localized high-grade undifferentiated pleomorphic sarcoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology
verfasst von
Melike Ozcelik
Mesut Seker
Emrah Eraslan
Sinan Koca
Dogan Yazilitas
Ozlem Ercelep
Ersin Ozaslan
Serap Kaya
Ilhan Hacibekiroglu
Serkan Menekse
Asude Aksoy
Burcu Yapar Taskoylu
Umut Varol
Erkan Arpaci
Aydin Ciltas
Berna Oksuzoglu
Nurullah Zengin
Mahmut Gumus
Mehmet Aliustaoglu
Publikationsdatum
10.11.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4359-1

Weitere Artikel der Ausgabe 4/2016

Tumor Biology 4/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.